Antibody drug conjugates (ADCs) transformed oncology, and bioconjugates are now expanding beyond ADCs. New modalities such as antibody oligonucleotide, peptide, degrader, and antibody fragment conjugates are enabling more precise targeting and new biology. This panel brings together pharma, biotech, venture, and CDMO leaders to discuss:
• Scientific breakthroughs driving new conjugate modalities
• Translating innovations into clinical development
• Manufacturing and quality challenges at scale
• Investment trends shaping the field
• The role of cross industry collaboration in future innovation
Tuesday, May 5, 15:00 - 15:45, room Kairo
| Name | Position | Institution |
|---|---|---|
| Jimmy Li | CEO | WuXi XDC |
WuXi XDC is a leading global CRDMO focused on antibody drug conjugates (ADC) and the broader bioconjugate market. It provides end-to-end contract research, development and manufacturing services for bioconjugates, including ADCs. Its services cover antibody and other bioconjugate intermediates, chemical payloads and linkers, as well as bioconjugate drug substances and drug products.
